H.R.716 - Access to Cancer Clinical Trials Act of 2009111th Congress (2009-2010)
|Sponsor:||Rep. Israel, Steve [D-NY-2] (Introduced 01/27/2009)|
|Committees:||House - Energy and Commerce; Education and Labor; Ways and Means|
|Latest Action:||01/28/2009 Referred to the Subcommittee on Health.|
This bill has the status Introduced
Here are the steps for Status of Legislation:
Subject — Policy Area:
- View subjects
Summary: H.R.716 — 111th Congress (2009-2010)All Bill Information (Except Text)
Introduced in House (01/27/2009)
Access to Cancer Clinical Trials Act of 2009 - Amends the Public Health Service Act, the Employee Retirement Income Security Act of 1974 (ERISA), and the Internal Revenue Code to prohibit a group health plan from: (1) denying an eligible participant or beneficiary participation in clinical trials related to the treatment of cancer that are federally funded or conducted under an investigational new drug application reviewed by the Food and Drug Administration (FDA); (2) denying (or limiting or imposing additional conditions on) the coverage of routine patient costs for items and services furnished in connection with such participation; or (3) discriminating against an individual on the basis of such participation. Includes as routine patient costs all items and services provided in the clinical trial that are otherwise generally available to a qualified individual, with certain exceptions.
Applies such prohibitions to coverage offered in the individual market.
Requires the Secretary of Health and Human Services to study the impact on group health plans and health insurance issuers of requiring them to cover routine patient care costs for individuals with serious and life threatening diseases other than cancer.